Silvio Inzucchi, MD: Diversifying Treatments for Cardiovascular Events


While some treatments did not result in reduced instances of strokes in patients, others such as GLP-1 agonists provided Dr. Inzucchi with new opportunities for cardiovascular disease prevention.

In a presentation at The Metabolic Institute of America’s (TMIOA) 2021 Heart in Diabetes sessions in New York, NY, Silvio Inzucchi, MD, Professor of Medicine at Smillow Cancer Hospital at Yale Medicine, acknowledged that glucose-lowering methods alone could not significantly reduce risk of stroke in patients.

In order to reduce stroke risk in patients in patients with diabetes, Inzuchci suggested clinicians look beyond the specific event and the traditional methods for treating it, which led to research regarding anti-diabetic medications and glucagon-like peptide-1 receptor GLP-1 agonists.

Earlier studies, such as the PROactive study, showed that the anti-diabetic medication pioglitazone was used to reduced major cardiovascular events by 16% in patients with type 2 diabetes and macro-vascular disease.

In an interview with HCPLive, Inzucchi noted how drugs like pioglitazone and new emerging drug classes with GLP-1 agonists could be used to prevent strokes and other cardiovascular issues.

In addition to preventing individual cardiovascular events, some of the drugs and treatment methods featured in the presentation were used to treat a wide array of cardiovascular complications, which Inzucchi believed is a crucial aspect of cardiovascular research.

“I think that it's important to talk about how drugs can prevent specific events,” Inzucchi said. “But broadly speaking, we're using these drugs to prevent all events, and I think that's one of the important take home messages.

Recent Videos
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Brendon Neuen, MBBS, PhD | Credit:
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.